Skip to main content
Premium Trial:

Request an Annual Quote

Aetna, Cigna, UnitedHealthcare to Cover Agendia's MammaPrint

NEW YORK (GenomeWeb) – Agendia announced today that its MammaPrint 70-gene signature breast cancer recurrence risk test has received positive coverage decisions from Aetna, Cigna, and UnitedHealthcare.

According to Agendia, the three insurers cover more than 85 million people in the US and internationally.

"The positive coverage decisions by these major healthcare insurers echo the rapidly increasing adoption of MammaPrint among US physicians who recognize the value of the test to personalize and, in many cases, de-escalate treatment for early breast cancer," Agendia Chief Medical Officer William Audeh said in a statement. "MammaPrint provides physicians with a binary low risk or high risk of recurrence result that has considerable quality of life and cost-saving implications."

Last year, Blue Shield of California and First Coast Service Options — the Medicare contractor for Florida, Puerto Rico, and the Virgin Islands — began covering MammaPrint. Also in 2017, the American Society of Clinical Oncology published revised early-stage breast cancer guidelines that feature a focused update recommending MammaPrint for guiding treatment decisions in early-stage breast cancer patients with one-to-three positive lymph nodes.